BARCELONA, Spain I March 14, 2021 I La Merie Publishing announced the release of the 15th edition of its annual report about sales of recombinant biologics. The report 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicsprovides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2020. For the first time in this report series, information about sales of novel biologics, i.e. gene & cell therapy and RNAi, is presented.
Global sales of branded originator biologics increased by 7.5% to US$ 240 bln compared with the previous year. More than 60 recombinant biologic therapeutics reached blockbuster status with 2020 sales exceeding US$ 1 bln (66% antibodies). Antibody sales represented more than 75% of total biologics sales in 2020.
Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.
Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies.
Development of sales of antibody-drug conjugates are also presented for the first time.
Methodology
Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 4, 2020. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
The report 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicscan be acquiredat La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2020-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
For those interested in historic sales data of biologics, La Merie Publishing offers a subscription to its online Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscriptionathttps://lamerie.com/report/sales-database-for-therapeutic-antibodies-proteins-1-year-subscription/. Subscription to the database includes a pdf copy of the most recent report about Biologics Sales.
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares proprietary reports for purchase in its online store and customized reports for clients. La Merie Publishing products can be purchased the online store www.lamerie.com and at selected Resellers.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 176
BARCELONA, Spain I March 14, 2021 I La Merie Publishing announced the release of the 15th edition of its annual report about sales of recombinant biologics. The report 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicsprovides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2020. For the first time in this report series, information about sales of novel biologics, i.e. gene & cell therapy and RNAi, is presented.
Global sales of branded originator biologics increased by 7.5% to US$ 240 bln compared with the previous year. More than 60 recombinant biologic therapeutics reached blockbuster status with 2020 sales exceeding US$ 1 bln (66% antibodies). Antibody sales represented more than 75% of total biologics sales in 2020.
Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.
Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies.
Development of sales of antibody-drug conjugates are also presented for the first time.
Methodology
Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 4, 2020. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
The report 2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologicscan be acquiredat La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2020-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/
For those interested in historic sales data of biologics, La Merie Publishing offers a subscription to its online Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscriptionathttps://lamerie.com/report/sales-database-for-therapeutic-antibodies-proteins-1-year-subscription/. Subscription to the database includes a pdf copy of the most recent report about Biologics Sales.
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares proprietary reports for purchase in its online store and customized reports for clients. La Merie Publishing products can be purchased the online store www.lamerie.com and at selected Resellers.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 176
